TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27228511

Group type: EXPERIMENTAL
Intervention: MILD
Number of subjects: 302

Group type: COMPARATOR
Intervention: Epidural Steroid Injections (ESIs)
Number of subjects: 302
Study: 24970708

Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Therapy (GCBT)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Internet-based guided self-help treatment (ICBT)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Web-based discussion forum (DF)
Number of subjects: 128
Study: 23427388

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) plus anti-infection and conventional medicine treatment
Number of subjects: 240

Group type: COMPARATOR
Intervention: Anti-infection plus conventional medicine treatment
Number of subjects: 240
Study: 20035541

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional surgery (saphenofemoral disconnection and stripping)
Number of subjects: 88
Study: 18720692

Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Triamcinolone acetonide (TAC) (20 mg)
Number of subjects: 20
Study: 15771319

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 60 mg once daily
Number of subjects: 7665
Study: 12819315

Group type: EXPERIMENTAL
Intervention: Educational programs providing individually tailored information
Number of subjects: 0

Group type: COMPARATOR
Intervention: Educational programs providing nontailored information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Educational protocols for participant-identified providers requiring active participation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Educational protocols for participant-identified providers requiring passive participation
Number of subjects: 0
Study: 10100645

Group type: EXPERIMENTAL
Intervention: Erbium:YAG laser systems (Candela, Continuum Biomedical, HGM, MDLT, SEO, Sharplan/ESC)
Number of subjects: 12
Study: 8666599

Group type: EXPERIMENTAL
Intervention: Pneumatic plantar compression and aspirin
Number of subjects: 122

Group type: COMPARATOR
Intervention: Aspirin alone (Control)
Number of subjects: 122
Study: 1870754

Group type: EXPERIMENTAL
Intervention: Azathioprine (after conversion from cyclosporin)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Cyclosporin (control group)
Number of subjects: 34
Study: 6224469

Group type: EXPERIMENTAL
Intervention: Thiabendazole (50 mg kg‐1 daily for two days)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Thiabendazole (100 mg kg‐1 daily for two days)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Metronidazole (30-40 mg kg‐1 t.d.s. for three days)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 31749064

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment (CBT)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 216
Study: 31118080

Group type: EXPERIMENTAL
Intervention: External skeletal fixation (ESF)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Volar locking plate fixation (VLPF)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Cast fixation
Number of subjects: 13
Study: 29396097

Group type: EXPERIMENTAL
Intervention: Anesthetists aware of NIRS data
Number of subjects: 41

Group type: COMPARATOR
Intervention: Anesthetists blinded to NIRS data
Number of subjects: 41
Study: 27366132

Group type: EXPERIMENTAL
Intervention: EX-30 (30 min moderate-intensity aerobic exercise)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: EX-60 (60 min moderate-intensity aerobic exercise)
Number of subjects: 12

Group type: COMPARATOR
Intervention: CON (sedentary control)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All interventions (EX-30, EX-60, CON)
Number of subjects: 12
Study: 24930580

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 191

Group type: COMPARATOR
Intervention: Perazine
Number of subjects: 191
Study: 21999719

Group type: EXPERIMENTAL
Intervention: Intensive intervention based on self-determination theory (SDT), involving 4 meetings over 6 months with study counselors
Number of subjects: 737

Group type: COMPARATOR
Intervention: Community care (CC) participants received smoking-cessation pamphlets and information on local treatment programs
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Intensive intervention based on SDT
Number of subjects: 737
Study: 19843797

Group type: EXPERIMENTAL
Intervention: Intrathecal hyperbaric bupivacaine 7 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intrathecal hyperbaric bupivacaine 8 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intrathecal hyperbaric bupivacaine 9 mg
Number of subjects: 60
Study: 17204951

Group type: EXPERIMENTAL
Intervention: Omeprazole (0.7 mg/kg/d)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 15501962

Group type: EXPERIMENTAL
Intervention: Recombinant erythropoietin plus indomethacin
Number of subjects: 108

Group type: COMPARATOR
Intervention: Indomethacin (control group)
Number of subjects: 108
Study: 11228177

Group type: EXPERIMENTAL
Intervention: Intravenous doxercalciferol (1alphaD(2))
Number of subjects: 70

Group type: COMPARATOR
Intervention: Oral doxercalciferol (1alphaD(2))
Number of subjects: 70
Study: 9442826

Group type: EXPERIMENTAL
Intervention: Oxymetazoline, 0.05% (w/v) in saline
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline nasal spray (placebo)
Number of subjects: 30
Study: 7931476

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) until disease progression
Number of subjects: 167

Group type: COMPARATOR
Intervention: Observation subsequent to local treatment
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 167
Study: 3495653

Group type: EXPERIMENTAL
Intervention: Formula containing 1.8 g protein/100 kcal with whey/casein ratios 18:82, 34:66, or 50:50
Number of subjects: 40

Group type: COMPARATOR
Intervention: Human milk
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Formula with reduced protein contents
Number of subjects: 40
Study: 29503036

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 127

Group type: COMPARATOR
Intervention: Loxoprofen
Number of subjects: 127
Study: 27107209

Group type: EXPERIMENTAL
Intervention: 8IU low dose intranasal oxytocin
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intravenous oxytocin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 24930697

Group type: EXPERIMENTAL
Intervention: Test meal (490 kcal)
Number of subjects: 30
Study: 23197541

Group type: EXPERIMENTAL
Intervention: E-point septal separation measurements
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: E-point septal separation as a continuous variable
Number of subjects: 103
Study: 20496733

Group type: EXPERIMENTAL
Intervention: Long snake moxibustion combined with functional exercise
Number of subjects: 78

Group type: COMPARATOR
Intervention: Sulfasalazine (oral administration)
Number of subjects: 78
Study: 18005471

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion (0.25 microg kg(‐1) min(‐1))
Number of subjects: 42

Group type: COMPARATOR
Intervention: Fentanyl (total dose 2.6 +/- 0.3 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 42
Study: 15956292

Group type: EXPERIMENTAL
Intervention: Vitamin D3-fortified process cheese (600 IU/d) for 2 months
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Vitamin D2-fortified cheese (5880 IU/56.7-g serving)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Water (32,750 IU/250 mL)
Number of subjects: 100
Study: 12109926

Group type: EXPERIMENTAL
Intervention: Antipsychotics (specific agents not detailed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: QTc-prolonging drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antipsychotics with marked QTc prolongation
Number of subjects: 0
Study: 10613427

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 10
Study: 7732330

Group type: EXPERIMENTAL
Intervention: Cisapride (20 mg twice daily) + Ranitidine (150 mg twice daily)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Cisapride (20 mg twice daily)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice daily)
Number of subjects: 197
Study: 2258379

Group type: EXPERIMENTAL
Intervention: Sertraline (50-200 mg/day)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Amitriptyline (50-150 mg/day)
Number of subjects: 241
Study: 6991103

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy with moderate doses of methotrexate and L-asparaginase added to standard doses of 5-fluorouracil, Adriamycin, and cyclophosphamide, along with Corynebacterium parvum or Pseudomonas vaccine.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pseudomonas vaccine
Number of subjects: 0
Study: 31849201

Group type: EXPERIMENTAL
Intervention: Egg intervention (one egg per day for 6 months during early complementary feeding)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Egg intervention group
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Current dietary egg intake
Number of subjects: 135
Study: 31690285

Group type: EXPERIMENTAL
Intervention: Midline approach (Group M)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Right approach (Group R)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 262
Study: 28403798

Group type: EXPERIMENTAL
Intervention: Cobicistat-boosted darunavir (800 mg) with 2 N(t)RTIs, once daily for 48 weeks
Number of subjects: 313
Study: 26022901

Group type: EXPERIMENTAL
Intervention: Small-bore pleural catheter (8 Fr) with manual aspiration
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard chest tube drainage (20-24 Fr)
Number of subjects: 49
Study: 23669567

Group type: EXPERIMENTAL
Intervention: Intravesical oxybutynin 10 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oral oxybutynin 5 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intravesical oxybutynin (7 doses of 10 mg)
Number of subjects: 20
Study: 21093925

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 45
Study: 19235072

Group type: EXPERIMENTAL
Intervention: Social-cognitive theories (e.g. Transtheoretical model, Theory of Planned Behaviour, Protection Motivation Theory, Social Cognitive Theory)
Number of subjects: 1183
Study: 15741734

Group type: EXPERIMENTAL
Intervention: Quinapril (ACE inhibitor)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Losartan (ARB)
Number of subjects: 57
Study: 12433761

Group type: EXPERIMENTAL
Intervention: Ultrasound screening for abdominal aortic aneurysms
Number of subjects: 67800

Group type: COMPARATOR
Intervention: Control group (not offered screening)
Number of subjects: 67800
Study: 10490297

Group type: EXPERIMENTAL
Intervention: Calcipotriol + UVB
Number of subjects: 178

Group type: COMPARATOR
Intervention: Vehicle + UVB
Number of subjects: 178

Group type: COMPARATOR
Intervention: Calcipotriol alone
Number of subjects: 178
Study: 8944120

Group type: EXPERIMENTAL
Intervention: Iopamidol 370 mg l/l
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ioxaglate 350 mg l/l
Number of subjects: 100

Group type: COMPARATOR
Intervention: Iopamidol 300 mg l/l
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ioxaglate 320 mg l/l
Number of subjects: 100
Study: 1720488

Group type: EXPERIMENTAL
Intervention: Isradipine at 1.25‐2.5 mg twice daily
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 6749440

Group type: EXPERIMENTAL
Intervention: Sulconazole nitrate 1.0 percent cream
Number of subjects: 96

Group type: COMPARATOR
Intervention: Miconazole nitrate 2.0 percent cream
Number of subjects: 96
Study: 31850996

Group type: COMPARATOR
Intervention: Standard intravenous fluid regimen (S-group)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Restrictive intravenous fluid regimen (R-group)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Preoperative NT-Pro-BNP
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Fluid volumes
Number of subjects: 135

Group type: COMPARATOR
Intervention: CPC vs no-CPC
Number of subjects: 135
Study: 31141394

Group type: EXPERIMENTAL
Intervention: Sports drink (Gatorade®); 805 ml fluid intake, 6.5 MJ energy intake, 187 g carbohydrate intake; p=0.002 for energy, p<0.001 for carbohydrate
Number of subjects: 132

Group type: COMPARATOR
Intervention: Water; 751 ml fluid intake, 5.7 MJ energy intake, 151 g carbohydrate intake
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Sports drink (Gatorade®); 1,047 ml acute fluid intake, 3,337 ml total fluid intake at end of trial days; p=0.004 for acute fluid intake, p<0.01 for total fluid intake
Number of subjects: 132

Group type: COMPARATOR
Intervention: Low-alcohol beer (Hahn Ultra®); 850 ml acute fluid intake, 2,982 ml total fluid intake at end of trial days
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Sports drink (Gatorade®); urine specific gravity 1.021
Number of subjects: 132

Group type: COMPARATOR
Intervention: Low-alcohol beer (Hahn Ultra®); urine specific gravity 1.016
Number of subjects: 132
Study: 28454674

Group type: EXPERIMENTAL
Intervention: 1/3 IPV‐Al
Number of subjects: 824

Group type: EXPERIMENTAL
Intervention: 1/5 IPV‐Al
Number of subjects: 824

Group type: EXPERIMENTAL
Intervention: 1/10 IPV‐Al
Number of subjects: 824

Group type: COMPARATOR
Intervention: IPV
Number of subjects: 824
Study: 25867599

Group type: EXPERIMENTAL
Intervention: Enzyme-Modified Ginseng Extract (EG) cream
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 22589421

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 118

Group type: COMPARATOR
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 118
Study: 22688223

Group type: EXPERIMENTAL
Intervention: Educational intervention and feedback tool for GPs, including a two-hour feedback session and training to generate eligible patient lists from EMR.
Number of subjects: 30000

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 30000

Group type: EXPERIMENTAL
Intervention: Educational intervention and feedback tool for GPs.
Number of subjects: 30000
Study: 19126049

Group type: EXPERIMENTAL
Intervention: Isotretinoin treatment group
Number of subjects: 78

Group type: COMPARATOR
Intervention: Topical treatment group
Number of subjects: 78
Study: 17823421

Group type: EXPERIMENTAL
Intervention: Lactoovovegetarian diet (LOV-D)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Standard calorie-restricted, low-fat omnivorous diet (STD-D)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Preference-No groups
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Both diets (LOV-D and STD-D)
Number of subjects: 176
Study: 16389910

Group type: EXPERIMENTAL
Intervention: Active treatment allocation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group allocation
Number of subjects: 0
Study: 12407487

Group type: EXPERIMENTAL
Intervention: Alcohol-based melaleuca oral solution, administered four times daily for 2-4 weeks
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Alcohol-free melaleuca oral solution, administered four times daily for 2-4 weeks
Number of subjects: 27
Study: 10509988

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 8748337

Group type: EXPERIMENTAL
Intervention: Topical anesthetic cream, EMLA
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo ointment (Vaseline)
Number of subjects: 54
Study: 1955605

Group type: EXPERIMENTAL
Intervention: Stress Inoculation Training (SIT)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Supportive Counseling (SC)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Wait-list Control (WL)
Number of subjects: 45
Study: 6754634

Group type: EXPERIMENTAL
Intervention: Labetalol (300 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: COMPARATOR
Intervention: Non-treatment (control)
Number of subjects: 6
Study: 30954936

Group type: EXPERIMENTAL
Intervention: Percutaneous peripheral nerve stimulation (PNS)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 28992513

Group type: EXPERIMENTAL
Intervention: Second Step Child Protection Unit videos
Number of subjects: 438

Group type: COMPARATOR
Intervention: Control group (watching videos on child obesity)
Number of subjects: 438
Study: 27321490

Group type: EXPERIMENTAL
Intervention: NPWT
Number of subjects: 32

Group type: COMPARATOR
Intervention: ADM
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: NPWT + ADM
Number of subjects: 32
Study: 25147070

Group type: EXPERIMENTAL
Intervention: n-3 FA 1g
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: n-3 FA 2g
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: n-3 FA 4g
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 20662863

Group type: EXPERIMENTAL
Intervention: Immediate implants placed in fresh extraction sockets
Number of subjects: 35
Study: 20595193

Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (ALC) 3 g/day
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (ALC) 1 g/day
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 17174460

Group type: EXPERIMENTAL
Intervention: Crocus sativus petal 15 mg bid (morning and evening)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fluoxetine 10 mg bid (morning and evening)
Number of subjects: 40
Study: 15843959

Group type: EXPERIMENTAL
Intervention: Dorsiflexors' ElectroStimulation (ES) training (4 weeks, 4 s/week, 40 min/session)
Number of subjects: 21
Study: 12473257

Group type: EXPERIMENTAL
Intervention: Perhexiline treatment for 3 days
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Perhexiline treatment
Number of subjects: 50
Study: 9523406

Group type: EXPERIMENTAL
Intervention: Heightened self-focus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spontaneous forms of stereotype suppression
Number of subjects: 0
Study: 7699528

Group type: EXPERIMENTAL
Intervention: Prednisone 1 mg/kg
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Prednisone 2 mg/kg
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study: 2617153

Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide (2.5 mg o.d.)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 910742

Group type: EXPERIMENTAL
Intervention: Vivonex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flexical
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Precision LR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31786114

Group type: EXPERIMENTAL
Intervention: Closed pleural technique (preservation of pleural integrity)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Open pleural procedure (without preservation of pleural integrity)
Number of subjects: 100
Study: 29698710

Group type: EXPERIMENTAL
Intervention: Carboxytherapy (1000 cm3 of CO2)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Carboxytherapy
Number of subjects: 16
Study: 27513714

Group type: EXPERIMENTAL
Intervention: 2000IU vitamin D3/day from weeks 26-28 until childbirth
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (not explicitly mentioned but implied as control)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 2000IU vitamin D3/day
Number of subjects: 28
Study: 24608494

Group type: EXPERIMENTAL
Intervention: Synchronized intermittent mandatory ventilation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pressure support ventilation with volume guarantee
Number of subjects: 60
Study: 22911072

Group type: EXPERIMENTAL
Intervention: Early removal of nasogastric tube (48 hours)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional nasogastric decompression for 6 to 10 days
Number of subjects: 150
Study: 20631209

Group type: EXPERIMENTAL
Intervention: Off-channel neuron activation during visual discrimination task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maximally responsive sensory neurons
Number of subjects: 0
Study: 18306372

Group type: EXPERIMENTAL
Intervention: Resistance exercise training (RET)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (AET)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Nontaxane-based therapies
Number of subjects: 242
Study: 16004047

Group type: EXPERIMENTAL
Intervention: Laser-induced autofluorescence (LIAF) combined with artificial neural network (ANN)
Number of subjects: 0
Study: 12854296

Group type: EXPERIMENTAL
Intervention: Relationship-enhancing program of care (REPC)
Number of subjects: 50
Study: 10506041

Group type: EXPERIMENTAL
Intervention: Single intravenous 2.2 g dose of co-amoxiclav
Number of subjects: 106

Group type: COMPARATOR
Intervention: Identical appearing saline (control)
Number of subjects: 106
Study: 8671156

Group type: EXPERIMENTAL
Intervention: Triptorelin (gonadotrophin-releasing hormone agonist)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no triptorelin)
Number of subjects: 66
Study: 2006616

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg/day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg 3 times daily)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combination therapy (Atenolol + Nifedipine)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 6751338

Group type: EXPERIMENTAL
Intervention: 80 micrograms atropine methonitrate
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Combination of 80 micrograms atropine methonitrate and 450 micrograms reproterol
Number of subjects: 17
Study: 31796028

Group type: EXPERIMENTAL
Intervention: Oral Health Care Package (OHCP) delivered to mothers of 1-6-year-old children
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care advice available at the AWCs
Number of subjects: 0